Centenary Institute receives grant for ovarian cancer research targeting chemotherapy resistance, led by Dr. Alex Cole.
The Centenary Institute received a grant from Cancer Australia to research new ovarian cancer treatments targeting chemotherapy resistance. Dr. Alex Cole will lead the project, focusing on blocking a protein called follistatin (FST) that makes cancer cells resistant to chemotherapy. By using molecular biology and directed evolution techniques, they aim to create nanobodies that could enhance chemotherapy effectiveness and improve ovarian cancer treatment rates.
April 02, 2024
3 Articles